Abstract

Glutamatergic dysregulation is implicated in the neurobiology of mood disorders. This study investigated the relationship between the anterior cingulate cortex (AC) glutamate, as measured by proton magnetic resonance spectroscopy (1H-MRS), and single-nucleotide polymorphisms (SNPs) from four genes (GLUL, SLC1A3, SLC1A2, and SLC1A7) that regulate the extracellular glutamate in 26 depressed patients with major depressive disorder (MDD; n = 15) and bipolar disorder (BD; n = 11). Two SNPs (rs3812778 and rs3829280), in perfect linkage disequilibrium, in the 3′ untranslated region of the EAAT2 gene SLC1A2, were associated with AC glutamate, with minor allele carriers having significantly higher glutamate levels (p < 0.001) in comparison with common allele homozygotes. In silico analysis revealed an association of minor allele carriers of rs3812778/rs382920 with an upregulation of the astrocytic marker CD44 localized downstream of SLC1A2 on chromosome 11. Finally, we tested the disease relevance of these SNPs in a large group of depressed patients [MDD (n = 458); BD (n = 1473)] and found that minor allele carriers had a significantly higher risk for rapid cycling (p = 0.006). Further work is encouraged to delineate the functional impact of excitatory amino acid transporter genetic variation on CD44 associated physiology and glutamatergic neurotransmission, specifically glutamate–glutamine cycling, and its contribution to subphenotypes of mood disorders.

Details

Title
Genetic variant in SLC1A2 is associated with elevated anterior cingulate cortex glutamate and lifetime history of rapid cycling
Author
Marin, Veldic 1 ; Millischer Vincent 2   VIAFID ORCID Logo  ; Port, John D 3   VIAFID ORCID Logo  ; Ho, Ada Man-Choi 4   VIAFID ORCID Logo  ; Yun-Fang, Jia 4 ; Geske, Jennifer R 5 ; Biernacka, Joanna M 6   VIAFID ORCID Logo  ; Backlund Lena 2   VIAFID ORCID Logo  ; McElroy, Susan L 7 ; Bond, David J 8 ; Carlos, Villaescusa J 2   VIAFID ORCID Logo  ; Skime Michelle 1 ; Choi Doo-Sup 9 ; Lavebratt Catharina 2   VIAFID ORCID Logo  ; Schalling, Martin 2 ; Frye, Mark A 1 

 Mayo Clinic, Department of Psychiatry and Psychology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Karolinska Institutet, Department of Molecular Medicine and Surgery (MMK), Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Neurogenetics Unit, Center for Molecular Medicine, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705) 
 Mayo Clinic, Department of Radiology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Department of Molecular Pharmacology & Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Department of Health Sciences Research, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Department of Psychiatry and Psychology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Department of Health Sciences Research, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 University of Cincinnati, Lindner Center of Hope, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593) 
 University of Minnesota, Department of Psychiatry, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657) 
 Mayo Clinic, Department of Psychiatry and Psychology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Department of Molecular Pharmacology & Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2229261444
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.